Peripheral neuropathies during biologic therapies

Mod Rheumatol. 2016;26(2):288-93. doi: 10.3109/14397595.2013.859770. Epub 2013 Dec 9.

Abstract

Peripheral neuropathies should be recognized as the adverse effects of biological agents, especially anti-TNF agents. However, no solid clinical databases for biological agent-associated peripheral neuropathies (BAPN) have been established in Japan. Here we report two cases of peripheral neuropathy associated with anti-TNF agents. One was peroneal motor neuropathy. The other case was chronic inflammatory demyelinating polyradiculoneuropathy. In addition, we summarize the previous reports on BAPN and discuss their prevalence rate, pathogenesis and management.

Keywords: Biological agents; Peripheral neuropathy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Female
  • Humans
  • Infliximab / adverse effects*
  • Infliximab / therapeutic use
  • Japan
  • Male
  • Middle Aged
  • Peripheral Nervous System Diseases / chemically induced*
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / chemically induced*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab